TNKase Articles
Pharmaco-invasive strategy including Metalyse comparable to primary PCI for STEMI patients
11 March 2013
Boeh Ing terminates Ph III Metalyse study
31 July 2006
BI and Genentech terminate TNKase/Metalyse trial
18 July 2005
Genentech
20 January 2003
Genentech posts $214M loss in 2nd qtr
22 July 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
Genentech third-qtr revenues jump 24%
16 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
ASSENT 3 trial shows new regimen benefit
24 August 2001
Net income increases 28% at Genentech
12 July 2001
BI's tenecteplase launched in UK
21 May 2001
New world market forecasts from DR
6 April 2001
Genentech net income rises 30% for 2000
23 January 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
BI wins positive opinion for Metalyse
10 November 2000
Genentech's TNKase shows one-year efficacy
30 August 2000
Genentech sales up 15%, but loss incurred
20 July 2000
Update - Genentech antibody for AMI disappoints
20 June 2000
Stock Commentary New York
8 June 2000
FDA approves TNKase from Genentech
5 June 2000
Genentech unveils new trials for tenecteplase
15 March 2000
Actelion and Genentech hook up for tezosentan
17 February 2000
COR's Integrilin plus thrombolytic in AMI
11 November 1999
Genentech files BLA for tenecteplase
3 August 1999
Genentech's 1st qtr product sales leap 42%
15 April 1999
Showing 1-35 of 35 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
